May 2005
Volume 46, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2005
Intraocular Pressure Elevation After Intraocular Triamcinolone Injection in Vitrectomized and Non–Vitrectomized Patients – A Prospective Study
Author Affiliations & Notes
  • J. Hernecki
    Ophthalmology, Hospital de Mollet, Barcelona, Spain
  • S. Martín
    Ophthalmology, Hospital Universitari Vall d'Hebron, Barcelona, Spain
  • A. Navarro
    Facultat de Medicina, Unitat de Bioestadística. Universitat Autònoma de Barcelona, Barcelona, Spain
  • L. Sararols
    Ophthalmology, Hospital Universitari Vall d'Hebron, Barcelona, Spain
  • R. Paradinas
    Ophthalmology, Hospital Universitari Vall d'Hebron, Barcelona, Spain
  • J. García Arumí
    Ophthalmology, Hospital Universitari Vall d'Hebron, Barcelona, Spain
  • Footnotes
    Commercial Relationships  J. Hernecki, None; S. Martín, None; A. Navarro, None; L. Sararols, None; R. Paradinas, None; J. García Arumí, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2005, Vol.46, 1459. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      J. Hernecki, S. Martín, A. Navarro, L. Sararols, R. Paradinas, J. García Arumí; Intraocular Pressure Elevation After Intraocular Triamcinolone Injection in Vitrectomized and Non–Vitrectomized Patients – A Prospective Study . Invest. Ophthalmol. Vis. Sci. 2005;46(13):1459.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: To compare intraocular pressure (IOP) elevation following intraocular triamcinolone injection in vitrectomized and non–vitrectomized eyes. Methods: 47 eyes of 47 consecutive patients with macular oedema of different aetiology or subretinal neovascularization in whom intravitreal triamcinolone was administered were studied prospectively. Eyes with pre–existing aqueous dynamics pathology such as glaucoma or uveitis were excluded from the study. 27 eyes were treated with 4 mg of triamcinolone alone while in the remaining 20 eyes 8 mg of triamcinolone was administered at the end of vitrectomy. The retinal surgery was indicated for reasons other than macular oedema, thus the patients were not randomised. Follow–up period was 6 months. Results: There was no statistically significant difference in age, pre–operative visual acuity or IOP between the two groups. Following the triamcinolone injection a significant rise in IOP was observed in both groups (with 42,1%, 38,5%, and 40% in the non–vitrectomy group, and 35,7%, 58,3%, and 16,7% in the vitrectomy group suffering more than 30% rise in IOP from the baseline at 1, 3, and 6 months, respectively, p<0,05). However, the only statistically significant difference between the two groups was at 3 months, with the vitrectomy group IOP being higher (p=0,032). One patint in the vitrectomy group had to undergo filtration surgery due to uncontrolled IOP. Apart from IOP rise, there were no major surgical complications in either group. Conclusions: There appears to be little difference in IOP rise following intravitreal injection of 4 mg triamcinolone in non–vitrectomized eyes and injection of 8 mg triamcinolone following pars plana vitrectomy during six–month follow–up. IOP does not seem to descend to baseline at six months after administration of intravitreal triamcinolone.

Keywords: intraocular pressure • vitreoretinal surgery • injection 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×